NO178870C - Fremgangsmåte for fremstilling av modifisert Eglin B eller C samt DNA, ekspresjonsvektor og vertsmikroorganisme - Google Patents

Fremgangsmåte for fremstilling av modifisert Eglin B eller C samt DNA, ekspresjonsvektor og vertsmikroorganisme

Info

Publication number
NO178870C
NO178870C NO890932A NO890932A NO178870C NO 178870 C NO178870 C NO 178870C NO 890932 A NO890932 A NO 890932A NO 890932 A NO890932 A NO 890932A NO 178870 C NO178870 C NO 178870C
Authority
NO
Norway
Prior art keywords
dna
preparation
expression vector
host microorganism
eglin
Prior art date
Application number
NO890932A
Other languages
English (en)
Norwegian (no)
Other versions
NO890932L (no
NO178870B (no
NO890932D0 (no
Inventor
Markus Gerhard Grutter
Dirk Heinz
Manfred Liersch
Original Assignee
Ciba Geigy Ag
Ucp Gen Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag, Ucp Gen Pharma Ag filed Critical Ciba Geigy Ag
Publication of NO890932D0 publication Critical patent/NO890932D0/no
Publication of NO890932L publication Critical patent/NO890932L/no
Publication of NO178870B publication Critical patent/NO178870B/no
Publication of NO178870C publication Critical patent/NO178870C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8261—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield
    • C12N15/8271—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance
    • C12N15/8279—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance
    • C12N15/8286—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance for insect resistance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
    • Y02A40/10—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in agriculture
    • Y02A40/146—Genetically Modified [GMO] plants, e.g. transgenic plants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/855—Proteins from animals other than mammals or birds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Pest Control & Pesticides (AREA)
  • Insects & Arthropods (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
NO890932A 1988-03-07 1989-03-06 Fremgangsmåte for fremstilling av modifisert Eglin B eller C samt DNA, ekspresjonsvektor og vertsmikroorganisme NO178870C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH84088 1988-03-07

Publications (4)

Publication Number Publication Date
NO890932D0 NO890932D0 (no) 1989-03-06
NO890932L NO890932L (no) 1989-09-08
NO178870B NO178870B (no) 1996-03-11
NO178870C true NO178870C (no) 1996-06-19

Family

ID=4196431

Family Applications (1)

Application Number Title Priority Date Filing Date
NO890932A NO178870C (no) 1988-03-07 1989-03-06 Fremgangsmåte for fremstilling av modifisert Eglin B eller C samt DNA, ekspresjonsvektor og vertsmikroorganisme

Country Status (20)

Country Link
US (1) US5079229A (OSRAM)
EP (1) EP0332576B1 (OSRAM)
JP (1) JP2716191B2 (OSRAM)
KR (1) KR0134377B1 (OSRAM)
AT (1) ATE103930T1 (OSRAM)
AU (1) AU623881B2 (OSRAM)
CA (1) CA1339105C (OSRAM)
DD (1) DD283645A5 (OSRAM)
DE (1) DE58907373D1 (OSRAM)
DK (1) DK107389A (OSRAM)
ES (1) ES2063161T3 (OSRAM)
FI (1) FI96116C (OSRAM)
HU (1) HU209401B (OSRAM)
IE (1) IE62993B1 (OSRAM)
IL (1) IL89496A0 (OSRAM)
NO (1) NO178870C (OSRAM)
NZ (1) NZ228208A (OSRAM)
PT (1) PT89916B (OSRAM)
TW (1) TW211522B (OSRAM)
ZA (1) ZA891679B (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6342373B1 (en) * 1983-11-21 2002-01-29 Ucp Gen-Pharma Ag Process for preparing recombinant eglin, protease inhibitor
US5674833A (en) * 1990-09-18 1997-10-07 Novo Nordisk A/S Detergent compositions containing protease and novel inhibitors for use therein
US5604201A (en) * 1993-01-08 1997-02-18 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non-Profit Organization Methods and reagents for inhibiting furin endoprotease
TW492975B (en) * 1993-07-26 2002-07-01 Novartis Ag Tryptase inhibitor
BR9711540A (pt) 1996-09-24 2001-06-19 Protector & Gamble Company Inibidores de protease proteìnico estabilizados e variantes dos mesmos
US7001884B2 (en) * 2001-06-18 2006-02-21 Regents Of The University Of Michigan Eglin c based drugs for treatment of disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2125047B (en) * 1982-08-09 1986-02-19 Ciba Geigy Ag Yeast hybrid vectors and their use for the production of polypeptides
DE3324534A1 (de) * 1983-07-07 1985-01-17 Ciba-Geigy Ag, Basel Modifizierte protease-inhibitoren, verfahren zu ihrer herstellung und daraus bereitete pharmazeutische mittel
FI86744C (fi) * 1983-11-21 1992-10-12 Ciba Geigy Ag Foerfarande foer framstaellning av eglinfoereningar
US4711848A (en) * 1984-03-14 1987-12-08 Zymogenetics, Inc. Site specific mutagenesis in alpha-1-antitrypsin
DE3585969D1 (de) * 1984-06-14 1992-06-11 Chiron Corp Protease-inhibitoren des alpha-1-antitrypsin typs mit modifizierter aktiever stelle und deren herstellung.
HU204563B (en) * 1984-12-06 1992-01-28 Synergen Biolog Inc Process for producing recombinant serine-protease inhibitors and dns sequencyes for them
GB2188322A (en) * 1986-03-26 1987-09-30 Bayer Ag Aprotinin and analogues thereof produced by a recombinant host
GB2199582A (en) * 1987-01-07 1988-07-13 Bayer Ag Analogues of pancreatic secretory trypsin inhibitor

Also Published As

Publication number Publication date
DE58907373D1 (de) 1994-05-11
IL89496A0 (en) 1989-09-10
IE890719L (en) 1989-09-07
FI96116B (fi) 1996-01-31
ATE103930T1 (de) 1994-04-15
NO890932L (no) 1989-09-08
KR0134377B1 (ko) 1998-04-20
JPH029392A (ja) 1990-01-12
HU209401B (en) 1994-05-30
FI891020L (fi) 1989-09-08
CA1339105C (en) 1997-07-29
EP0332576A3 (en) 1990-09-12
ES2063161T3 (es) 1995-01-01
AU623881B2 (en) 1992-05-28
JP2716191B2 (ja) 1998-02-18
DD283645A5 (de) 1990-10-17
AU3095989A (en) 1989-09-07
EP0332576B1 (de) 1994-04-06
PT89916A (pt) 1989-11-10
KR890014735A (ko) 1989-10-25
NO178870B (no) 1996-03-11
DK107389D0 (da) 1989-03-06
IE62993B1 (en) 1995-03-08
FI96116C (fi) 1996-05-10
TW211522B (OSRAM) 1993-08-21
NO890932D0 (no) 1989-03-06
HUT50503A (en) 1990-02-28
ZA891679B (en) 1989-10-25
EP0332576A2 (de) 1989-09-13
NZ228208A (en) 1990-08-28
PT89916B (pt) 1994-05-31
US5079229A (en) 1992-01-07
FI891020A0 (fi) 1989-03-03
DK107389A (da) 1989-09-08

Similar Documents

Publication Publication Date Title
DE3471688D1 (en) Dna vectors and their use in recombinant dna technology
NO871785D0 (no) Fremgangsmaate for fremstilling av et proteinprodukt, samt vektorsystem for fremgangsmaatens utfoerelse.
BR8301918A (pt) Proteina,sequencia de dna,veiculo de expressao replicavel,microorganismo ou cultura celular,plasmideo,composicao,cultura de celulas,utilizacao de tal proteina,processo de expressao,processo para producao de um veiculo de expressao e processo para preparacao de uma proteina uroquinase
AU2058888A (en) Variants of bovine pancreatic trypsin inhibitor produced by recombinant DNA technology, process, expression vector and recombinant host therefor and pharmaceutical use thereof
DE69529219D1 (en) Helicobacter proteine und impstoffe
ATE188740T1 (de) Viruspartikel mit veraendertem wirtspektrum
AU2768195A (en) Pigment epithelium-derived factor: characterization, genomic organization and sequence of the pedf gene
MY103362A (en) Production of proteins in active forms
HUP9900750A2 (hu) Gén kifejezésére szolgáló promóterek
HUT68379A (en) Method for modifying the cell, tissue or host tropism of a recombinant microorganism obtained this way and use thereof in medicine and veterinary medicine
HU895788D0 (en) Process for producing peptides and medical products containing them
ATE122720T1 (de) Virales vektorsystem zum einführen fremder dns- expressionserzeugnisse in gallinaceenvögeln.
FI964186A0 (fi) Ei-liittävät gp350/220-variantit
AU3095989A (en) Modified proteins
CA2037677A1 (en) Process for production of exogenous gene or its product in plant cells
ZA894181B (en) Amblyommin,a new active substance for anticoagulant therapy
WO1992011370A3 (de) Von proteinen des hepatitis c-virus abgeleitete polypeptide und deren verwendung
EP0270114A3 (de) ENV/GAG-Polypeptide
WO1990012807A3 (en) Purified, highly specific antibodies against gene products including retinoblastoma and method
EP0490383A3 (en) Peptides of the hiv-gag protein, their preparation and use
TR200002611T2 (tr) Beta-lipotropin ve kullanımları
FI870501L (fi) Menetelmä melanoomaan liittyvän p97-antigeenin antigeenisen sukulaispeptidin tai -proteiinin valmistamiseksi, sekä siinä käyttökelpoiset yhdistelmävirukset, yhdistelmävektorit ja isäntäsolut
AU1948788A (en) Expression of immunologically active proteins of human b-lymphotropic virus
NO962023L (no) Endotelin-konverterende enzym
EP0339569A3 (en) Expression of the hiv 24 kda gag protein in methylotrophic yeasts

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees

Free format text: LAPSED IN SEPTEMBER 2003